Table 4.

Summary of international expert votes on the importance of various clinical and laboratory outcome variables to measuring disease activity in sJIA.

No. VotesOutcome Variable
141No. joints with active arthritis by physician assessment
109No. days of fever in the last 2 weeks
92Erythrocyte sedimentation rate
92Patient’s global assessment of disease activity
75Parent’s global assessment of disease activity
74sJIA rash by physician examination
71C-reactive protein
53No. min with morning stiffness in the last 2 weeks
51Platelet count
49No. swollen joints by physician assessment
49Increased or new medications
48CHAQ overall score
46Parent’s global measure of severity
37sJIA rash by patient history
29Discontinued/added/changed medications
28No. joints with decreased range of motion by physician assessment
28White blood cell count
26Parent’s global measure of impact
17Patient-rated quality of life
16Neutrophil count
14Patient’s global measure of overall pain
8Patient’s global measure of joint pain
7Parent’s global measure of pain
6Patient-related fatigue
4Chest pain by patient history
3Decrease in physical activity level as indicated by patient
3Reduction of height velocity
1Alanine transaminase
1No. days with a sore throat in the last 2 weeks
0Aspartate transaminase
0Mean cell volume
0Patient’s global measure of muscle pain
  • sJIA: systemic juvenile idiopathic arthritis; CHAQ: Childhood Health Assessment Questionnaire.